Author

Tabitha McLachlan

Hunter Medical Research InstituteORCID 0000-0002-6633-974XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Abdul MannaniD· 1 shared Alicia M. DouglasiD· 1 shared Andrew H. WeiiD· 1 shared Anoop Kumar EnjetiiD· 1 shared Brett NixoniD· 1 shared Bryce C. ThomasiD· 1 shared David Anthony Skerrett-ByrneiD· 1 shared David Mossman· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abdul MannanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintJul 26, 2024

Adaptive resistance to FLT3 inhibitors is potentiated by ROS-driven DNA repair signalling

Dilana Elisabeth Staudt, Zacary P. Germon, Abdul Mannan…·Matthew D. Dun

This study identifies ATM-driven DNA repair and ROS addiction as mechanisms of resistance to FLT3 inhibitors in AML and shows ATM inhibition can overcome resistance in vitro and in vivo.

DOI 10.1101/2024.07.26.605229

humanbulk RNA-seq

𝕏 PostBluesky